SCHEMBL6764983

SCHEMBL6764983

O=c1[nH]cncc1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.53
IDO1 P14902 2/20 0.53
PDPK1 O15530 1/20 0.46
PARP1 P09874 1/20 0.46
ADRA1D P25100 1/20 0.45
ADRA1A P35348 1/20 0.45
ADRA1B P35368 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HPGDS O60760 1/20 0.44
ALDH1A1 P00352 2/20 0.44
SRC P12931 1/20 0.44
HRH3 Q9Y5N1 2/20 0.44
MAPT P10636 1/20 0.43
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12263263 0.80 MKNK1 (0.47) ALDH1A1KDM4ETSHR
SCHEMBL31618382 0.79 IDO1 (0.61) CYP3A4IDO1CYP17A1DYRK1ATAAR1
SCHEMBL31618364 0.76 PARP1 (0.41) IDO1PARP1SMN1; SMN2MAPTTAAR1
SCHEMBL27679889 0.75 MAPT (0.64) CYP3A4PARP1ALDH1A1MAPTKDM4E
SCHEMBL8802289 0.72 DAO (0.47) NPC1RAB9AMAPTDYRK1AATM
Bromide SCHEMBL9142238 0.72 QDPR (0.44) CYP3A4IDO1CYP17A1DYRK1A
Biphenyl SCHEMBL27655588 0.71 ALDH1A1 (0.70) CYP3A4IDO1ADRA1DADRA1AADRA1B
SCHEMBL27577902 0.71 IDO1 (0.91) CYP3A4IDO1SMN1; SMN2HPGDSMAPT
SCHEMBL25248458 0.71 MAPT (0.50) CYP3A4PARP1RAB9AALDH1A1MAPT
SCHEMBL311306 0.70 IDO1 (1.00) CYP3A4IDO1SMN1; SMN2HPGDSMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025119351-A1 GPR139 AGONIST 深圳湾实验室 2025-06-12 WO disclosed
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
WO-2010072598-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 WO disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS RFC1, RRP1B, RRBP1 CYP3A4 978/4885IDO1 2177/4885PDPK1 3700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.